[Efficacy of emoxypine in combined therapy for elderly patients with postinfarct cardiosclerosis and heart failure].
Forty-four patients with coronary heart disease, angina pectoris, prior myocardial infarction, and NYHA Functional Class II-IV heart failure were examined. Group 1 patients received emoxypine during combined therapy (CT). Group 2 patients took CT alone (a control group). The results of the study suggest that emoxypine significantly improves the clinical symptomatology and shows marked antianginal and antiischemic effects. As compared with the control group, Group 1 shows a more significant hemodynamic improvement. Moreover, the inclusion of emoxypine into CT for elderly patients with prior myocardial infarction produces a normalizing effect on oxidative stress. By taking into account the foregoing, it should be stated that it is expedient to include emoxypine into CT for this category of patients.
Zaslavskaia
R M
RM
Lilitsa
G V
GV
Kalinina
E V
EV
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004232:Diuretics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015150:Echocardiography, Doppler; D015716:Electrocardiography, Ambulatory; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009203:Myocardial Infarction / Q000150:complications; D010847:Picolines / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D005343:Fibrinolytic Agents; D010847:Picolines; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; C009820:6-methyl-2-ethyl-3-hydroxypyridine